Andrea Parriott1, James G Kahn1,2, Haleh Ashki1, Adam Readhead3, Pennan M Barry3, Alex J Goodell4, Jennifer Flood3, Priya B Shete5. 1. 8785 Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco, CA, USA. 2. 8785 Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA. 3. 117025 Tuberculosis Control Branch, California Department of Public Health, Richmond, CA, USA. 4. 8785 School of Medicine, University of California, San Francisco, CA, USA. 5. 8785 Division of Pulmonary and Critical Care Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, CA, USA.
Abstract
OBJECTIVE: Targeted testing and treatment of persons with latent tuberculosis infection (LTBI) is a critical component of the US tuberculosis (TB) elimination strategy. In January 2016, the California Department of Public Health issued a tool and user guide for TB risk assessment (California tool) and guidance for LTBI testing, and in September 2016, the US Preventive Services Task Force (USPSTF) issued recommendations for LTBI testing in primary care settings. We estimated the epidemiologic effect of adherence to both recommendations in California. METHODS: We used an individual-based Markov micro-simulation model to estimate the number of cases of TB disease expected through 2026 with baseline LTBI strategies compared with implementation of the USPSTF or California tool guidance. We estimated the risk of LTBI by age and country of origin, the probability of being in a targeted population, and the probability of presenting for primary care based on available data. We assumed 100% adherence to testing guidance but imperfect adherence to treatment. RESULTS: Implementation of USPSTF and California tool guidance would result in nearly identical numbers of tests administered and cases of TB disease prevented. Perfect adherence to either recommendation would result in approximately 7000 cases of TB disease averted (40% reduction compared with baseline) by 2026. Almost all of this decline would be driven by a reduction in the number of cases among non-US-born persons. CONCLUSIONS: By focusing on the non-US-born population, adherence to LTBI testing strategies recommended by the USPSTF and the California tool could substantially reduce the burden of TB disease in California in the next decade.
OBJECTIVE: Targeted testing and treatment of persons with latent tuberculosis infection (LTBI) is a critical component of the US tuberculosis (TB) elimination strategy. In January 2016, the California Department of Public Health issued a tool and user guide for TB risk assessment (California tool) and guidance for LTBI testing, and in September 2016, the US Preventive Services Task Force (USPSTF) issued recommendations for LTBI testing in primary care settings. We estimated the epidemiologic effect of adherence to both recommendations in California. METHODS: We used an individual-based Markov micro-simulation model to estimate the number of cases of TB disease expected through 2026 with baseline LTBI strategies compared with implementation of the USPSTF or California tool guidance. We estimated the risk of LTBI by age and country of origin, the probability of being in a targeted population, and the probability of presenting for primary care based on available data. We assumed 100% adherence to testing guidance but imperfect adherence to treatment. RESULTS: Implementation of USPSTF and California tool guidance would result in nearly identical numbers of tests administered and cases of TB disease prevented. Perfect adherence to either recommendation would result in approximately 7000 cases of TB disease averted (40% reduction compared with baseline) by 2026. Almost all of this decline would be driven by a reduction in the number of cases among non-US-born persons. CONCLUSIONS: By focusing on the non-US-born population, adherence to LTBI testing strategies recommended by the USPSTF and the California tool could substantially reduce the burden of TB disease in California in the next decade.
Authors: Leila C Kahwati; Cynthia Feltner; Michael Halpern; Carol L Woodell; Erin Boland; Halle R Amick; Rachel Palmieri Weber; Daniel E Jonas Journal: JAMA Date: 2016-09-06 Impact factor: 56.272
Authors: K Lönnroth; Z Mor; C Erkens; J Bruchfeld; R R Nathavitharana; M J van der Werf; C Lange Journal: Int J Tuberc Lung Dis Date: 2017-06-01 Impact factor: 2.373
Authors: Suzanne M Marks; David W Dowdy; Nicolas A Menzies; Priya B Shete; Joshua A Salomon; Andrea Parriott; Sourya Shrestha; Jennifer Flood; Andrew N Hill Journal: Public Health Rep Date: 2020 Jul/Aug Impact factor: 2.792
Authors: Deron C Burton; Scott Burris; Jonathan H Mermin; David W Purcell; Sara C Zeigler; Lara Bull-Otterson; Hazel D Dean Journal: Public Health Rep Date: 2020 Jul/Aug Impact factor: 2.792
Authors: Ali Mirzazadeh; James G Kahn; Maryam B Haddad; Andrew N Hill; Suzanne M Marks; Adam Readhead; Pennan M Barry; Jennifer Flood; Jonathan H Mermin; Priya B Shete Journal: PLoS One Date: 2021-04-01 Impact factor: 3.240
Authors: Heidi Fischer; Lei Qian; Jacek Skarbinski; Katia J Bruxvoort; Rong Wei; Kris Li; Laura B Amsden; Mariah S Wood; Abigail Eaton; Brigitte C Spence; Sally F Shaw; Sara Y Tartof Journal: PLoS One Date: 2022-08-25 Impact factor: 3.752